- Active Substance: Retatrutide
- Concentration: 10 mg per vial
- Pack Size: 1 vial
- Manufacturer: Generic Peptides
- Brand Name: Retatrutide
- Synonyms: LY3437943
- Molecular Formula: C187H291N51O58
- Molecular Weight: ~4200 g/mol
- Sequence: Proprietary Analog of GLP-1/GIP/Glucagon Tri-agonist
SKU: P4372
Retatrutide 10 mg – Advanced Tri-Agonist Research Peptide
Product Information
Retatrutide 10 mg is a high-purity injectable peptide manufactured by Generic Peptides for non-clinical, in-vitro research use. Each vial contains 10 mg of lyophilized Retatrutide, also known as LY3437943, formulated for stability and reproducibility in laboratory settings. With its unique tri-agonist mechanism, Retatrutide activates GLP-1, GIP, and glucagon receptors, offering researchers a multi-pathway approach to studying metabolic conditions. It is being explored in a variety of models, including obesity, insulin resistance, and age-related hormonal decline. Researchers prefer Retatrutide due to its robust receptor activity and promising data from early investigational studies.
Product Description
As a synthetic peptide analog, Retatrutide is engineered for enhanced receptor selectivity and pharmacodynamic stability. It has shown superior results in preclinical studies compared to mono-agonists like Semaglutide or Tirzepatide, due to its synergistic effect across three hormonal pathways. Supplied in lyophilized powder form, the product allows for flexible reconstitution and dosing in both acute and chronic research models. Laboratories investigating energy metabolism, appetite regulation, and hormonal modulation increasingly incorporate Retatrutide in experimental designs. The 10 mg vial format supports controlled study conditions and detailed pharmacological analysis.
Mechanism of Action
Retatrutide acts as a tri-agonist, simultaneously stimulating GLP-1, GIP, and glucagon receptors. GLP-1 (glucagon-like peptide-1) reduces appetite, enhances insulin secretion, and slows gastric emptying. GIP (gastric inhibitory polypeptide) supports lipid metabolism and further stimulates insulin response, particularly after meals. Glucagon receptor activation increases energy expenditure and lipolysis, making it beneficial in fat loss and body recomposition studies. The interaction of these pathways promotes metabolic balance, energy optimization, and glucose control, all of which are critical for aging-related and metabolic research. Its triple-action profile positions Retatrutide at the frontier of metabolic peptide investigation.
Use Case
From the viewpoint of an Anti-Aging Specialist, Retatrutide 10 mg presents a compelling tool for addressing the metabolic shifts associated with aging. Studies suggest that improved insulin sensitivity and fat loss contribute to extended healthspan and reduced disease risk. Retatrutide's influence on appetite, energy utilization, and lipid mobilization may be beneficial in reversing age-associated metabolic decline. It is also being evaluated for its potential to enhance mitochondrial efficiency and reduce inflammatory markers. As aging research evolves, Retatrutide may become a key agent in strategies aimed at preserving vitality and physiological resilience.
FAQ
What is Retatrutide used for in research?
Retatrutide is used to study metabolic disorders, including obesity, insulin resistance, and related age-associated conditions. It is also evaluated in models of fat loss, appetite suppression, and endocrine function. Its triple-receptor activity makes it valuable in exploring synergistic hormonal effects. Researchers are especially interested in its potential to mimic and enhance natural metabolic pathways. Note that it is strictly for research and not approved for clinical use.
Is Retatrutide approved for human use?
No, Retatrutide is not approved by the FDA or any regulatory body for human use. It is sold for research purposes only and should not be used for therapeutic or diagnostic applications. Handling is limited to licensed professionals in controlled environments. Misuse can result in regulatory or legal consequences. Always verify legal status before acquisition.
How does Retatrutide compare to other peptides?
Unlike single-pathway peptides such as Semaglutide (GLP-1) or Tesamorelin (GHRH), Retatrutide activates three receptors—GLP-1, GIP, and glucagon. This multifaceted approach allows for enhanced regulation of glucose, appetite, and energy expenditure. Early data suggest stronger metabolic responses and improved outcomes in obesity models. It's an advanced tool for comprehensive metabolic research. Its growing popularity in the longevity field reflects its wide-ranging potential.
Legal & Compliance Block
This product is sold exclusively for laboratory research and development use. It is not approved for human consumption, medical, or diagnostic use. Purchase is restricted to licensed researchers, institutions, and qualified professionals. All applicable local, state, and federal regulations must be followed.